TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive In Brief: Wyngaarden Suspends NIH Funds for Pennsylvania Head Injury Center Over Animal Care Problems July 26, 1985
TCL Archive Lung Screening Study Ties Up Advisors, Board Sends It Back To NCI For Revision. June 29, 2001
